argenx (ENXTBR:ARGX) Is Up 7.4% After Positive VYVGART Trial Results for Seronegative gMG – What's Changed

• Earlier in September 2025, argenx announced that its ADAPT SERON study for VYVGART achieved statistically significant and clinically meaningful results for treating AChR-Ab seronegative generalized myasthenia gravis, successfully meeting its primary endpoint and supporting a label expansion submission.
• This outcome marks a significant step for argenx, highlighting the potential to expand VYVGART's addressable market and strengthen its long-term position in the U.S. autoimmune treatment landscape.
• We'll examine how these positive trial results may reshape argenx's investment narrative and future growth drivers in autoimmune therapeutics.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

argenx Investment Narrative Recap

To hold shares in argenx, you need confidence in its ability to continually expand VYVGART into new indications and markets while maintaining healthy margins and navigating a sharpening competitive field. The recent positive ADAPT SERON trial results could meaningfully boost the most important short-term catalyst, further U.S. label expansion, but they do little to reduce the key risk: ongoing pressure from larger, established competitors and margin-impacting payer dynamics that could still weigh heavily on earnings potential.

Among argenx's recent announcements, the pivotal ADAPT SERON study outcome and planned FDA submission stand out most directly. This news, if followed by approval, would support a crucial push into the AChR-Ab seronegative gMG segment, enhancing VYVGART's competitive and commercial opportunity at a time when payer scrutiny and pricing headwinds remain active catalysts and risks for investors.

By contrast, the competitive environment in U.S. autoimmune drugs means any gains from new indications must be measured against...

Read the full narrative on argenx (it's free!)

argenx's outlook anticipates $6.9 billion in revenue and $2.6 billion in earnings by 2028. This implies a 30.6% annual revenue growth rate and an $1.3 billion earnings increase from current earnings of $1.3 billion.

Uncover how argenx's forecasts yield a €712.24 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community members provided fair value estimates for argenx, ranging from €530.28 to €1,334.45 per share. While community opinions vary, timely label expansions could shape the company's future value in ways analysts and individual investors weigh differently.

Explore 5 other fair value estimates on argenx - why the stock might be worth over 2x more than the current price!

Build Your Own argenx Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your argenx research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free argenx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate argenx's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com